Cargando…

Performance and correlation of ten commercial immunoassays for the detection of SARS-CoV-2 antibodies

Accurate immunoassays with a good correlation to neutralizing antibodies are required to support SARS-CoV-2 diagnosis, management, vaccine deployment, and epidemiological investigation. We conducted a study to evaluate the performance and correlation of the surrogate virus neutralization test (sVNT)...

Descripción completa

Detalles Bibliográficos
Autores principales: Lokida, Dewi, Karyana, Muhammad, Kosasih, Herman, Mardian, Yan, Sugiyono, Retna Indah, Arlinda, Dona, Lukman, Nurhayati, Salim, Gustiani, Butar butar, Deni Pepy, Naysilla, Adhella Menur, Irmansyah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783098/
https://www.ncbi.nlm.nih.gov/pubmed/36575657
http://dx.doi.org/10.1016/j.heliyon.2022.e12614
_version_ 1784857497092227072
author Lokida, Dewi
Karyana, Muhammad
Kosasih, Herman
Mardian, Yan
Sugiyono, Retna Indah
Arlinda, Dona
Lukman, Nurhayati
Salim, Gustiani
Butar butar, Deni Pepy
Naysilla, Adhella Menur
Irmansyah
author_facet Lokida, Dewi
Karyana, Muhammad
Kosasih, Herman
Mardian, Yan
Sugiyono, Retna Indah
Arlinda, Dona
Lukman, Nurhayati
Salim, Gustiani
Butar butar, Deni Pepy
Naysilla, Adhella Menur
Irmansyah
author_sort Lokida, Dewi
collection PubMed
description Accurate immunoassays with a good correlation to neutralizing antibodies are required to support SARS-CoV-2 diagnosis, management, vaccine deployment, and epidemiological investigation. We conducted a study to evaluate the performance and correlation of the surrogate virus neutralization test (sVNT) and other commercial immunoassays. We tested 107 sera of COVID-19 confirmed cases from three different time points, 58 confirmed non-COVID-19 sera, and 52 sera collected before the pandemic with two sVNTs, seven chemiluminescent assays, and one fluorescein assay. All assays achieved excellent sensitivity (95%–100%, ≥15 days after onset of illness), specificity (95.5%–100%), and showed moderate to high correlation with GenScript sVNT (r = 0.58 to r = 0.98), except Roche total antibodies (r = 0.48). Vazyme sVNT and Siemens total antibodies showed the highest correlation with GenScript sVNT (r = 0.98 and 0.88, respectively). Median indexes that may be used to estimate sera with the highest ability to inhibit SARS-CoV-2 and ACE-2 receptor attachment (GenScript sVNT inhibition 90%–100%) were 6.9 S/C (Abbott IgG), 161.9 COI (FREND™ IgG), 16.8 AU/ml (Snibe IgG), 40.1 S/CO (Beckman IgG), 281.9 U/ml (Mindray IgG), 712.2 U/ml (Mindray total antibodies), >10 index (Siemens total antibodies), and 95.3% inhibition (Vazyme sVNT). All ten commercial COVID-19 serology assays, with different targeting antigens, demonstrated a reliable performance, supporting the utility of those assays in clinical and research settings. However, further studies using more samples are needed to refine the results of evaluating the performances of these marketed serological assays. Reliable serological assays would be useful for clinicians, researchers and epidemiologists in confirming SARS-CoV-2 infections, observing SARS-CoV-2 transmission, and immune response post infection and vaccination, leading to better management and control of the disease.
format Online
Article
Text
id pubmed-9783098
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-97830982022-12-23 Performance and correlation of ten commercial immunoassays for the detection of SARS-CoV-2 antibodies Lokida, Dewi Karyana, Muhammad Kosasih, Herman Mardian, Yan Sugiyono, Retna Indah Arlinda, Dona Lukman, Nurhayati Salim, Gustiani Butar butar, Deni Pepy Naysilla, Adhella Menur Irmansyah Heliyon Research Article Accurate immunoassays with a good correlation to neutralizing antibodies are required to support SARS-CoV-2 diagnosis, management, vaccine deployment, and epidemiological investigation. We conducted a study to evaluate the performance and correlation of the surrogate virus neutralization test (sVNT) and other commercial immunoassays. We tested 107 sera of COVID-19 confirmed cases from three different time points, 58 confirmed non-COVID-19 sera, and 52 sera collected before the pandemic with two sVNTs, seven chemiluminescent assays, and one fluorescein assay. All assays achieved excellent sensitivity (95%–100%, ≥15 days after onset of illness), specificity (95.5%–100%), and showed moderate to high correlation with GenScript sVNT (r = 0.58 to r = 0.98), except Roche total antibodies (r = 0.48). Vazyme sVNT and Siemens total antibodies showed the highest correlation with GenScript sVNT (r = 0.98 and 0.88, respectively). Median indexes that may be used to estimate sera with the highest ability to inhibit SARS-CoV-2 and ACE-2 receptor attachment (GenScript sVNT inhibition 90%–100%) were 6.9 S/C (Abbott IgG), 161.9 COI (FREND™ IgG), 16.8 AU/ml (Snibe IgG), 40.1 S/CO (Beckman IgG), 281.9 U/ml (Mindray IgG), 712.2 U/ml (Mindray total antibodies), >10 index (Siemens total antibodies), and 95.3% inhibition (Vazyme sVNT). All ten commercial COVID-19 serology assays, with different targeting antigens, demonstrated a reliable performance, supporting the utility of those assays in clinical and research settings. However, further studies using more samples are needed to refine the results of evaluating the performances of these marketed serological assays. Reliable serological assays would be useful for clinicians, researchers and epidemiologists in confirming SARS-CoV-2 infections, observing SARS-CoV-2 transmission, and immune response post infection and vaccination, leading to better management and control of the disease. Elsevier 2022-12-23 /pmc/articles/PMC9783098/ /pubmed/36575657 http://dx.doi.org/10.1016/j.heliyon.2022.e12614 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Lokida, Dewi
Karyana, Muhammad
Kosasih, Herman
Mardian, Yan
Sugiyono, Retna Indah
Arlinda, Dona
Lukman, Nurhayati
Salim, Gustiani
Butar butar, Deni Pepy
Naysilla, Adhella Menur
Irmansyah
Performance and correlation of ten commercial immunoassays for the detection of SARS-CoV-2 antibodies
title Performance and correlation of ten commercial immunoassays for the detection of SARS-CoV-2 antibodies
title_full Performance and correlation of ten commercial immunoassays for the detection of SARS-CoV-2 antibodies
title_fullStr Performance and correlation of ten commercial immunoassays for the detection of SARS-CoV-2 antibodies
title_full_unstemmed Performance and correlation of ten commercial immunoassays for the detection of SARS-CoV-2 antibodies
title_short Performance and correlation of ten commercial immunoassays for the detection of SARS-CoV-2 antibodies
title_sort performance and correlation of ten commercial immunoassays for the detection of sars-cov-2 antibodies
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783098/
https://www.ncbi.nlm.nih.gov/pubmed/36575657
http://dx.doi.org/10.1016/j.heliyon.2022.e12614
work_keys_str_mv AT lokidadewi performanceandcorrelationoftencommercialimmunoassaysforthedetectionofsarscov2antibodies
AT karyanamuhammad performanceandcorrelationoftencommercialimmunoassaysforthedetectionofsarscov2antibodies
AT kosasihherman performanceandcorrelationoftencommercialimmunoassaysforthedetectionofsarscov2antibodies
AT mardianyan performanceandcorrelationoftencommercialimmunoassaysforthedetectionofsarscov2antibodies
AT sugiyonoretnaindah performanceandcorrelationoftencommercialimmunoassaysforthedetectionofsarscov2antibodies
AT arlindadona performanceandcorrelationoftencommercialimmunoassaysforthedetectionofsarscov2antibodies
AT lukmannurhayati performanceandcorrelationoftencommercialimmunoassaysforthedetectionofsarscov2antibodies
AT salimgustiani performanceandcorrelationoftencommercialimmunoassaysforthedetectionofsarscov2antibodies
AT butarbutardenipepy performanceandcorrelationoftencommercialimmunoassaysforthedetectionofsarscov2antibodies
AT naysillaadhellamenur performanceandcorrelationoftencommercialimmunoassaysforthedetectionofsarscov2antibodies
AT irmansyah performanceandcorrelationoftencommercialimmunoassaysforthedetectionofsarscov2antibodies